Related Experiment Video
Updated: May 16, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
A review of calcium supplements and cardiovascular disease risk
Robert P Heaney1, Stephen Kopecky, Kevin C Maki
1Osteoporosis Research Center, Creighton University Medical Center, Omaha, NE, USA.
Insights
Current evidence does not support a link between calcium supplements and cardiovascular events. Experts suggest current recommendations for bone health should remain unchanged.
Area of Science:
- Nutrition Science
- Cardiovascular Epidemiology
- Bone Health Research
Background:
- Concerns exist regarding potential cardiovascular risks associated with calcium supplement use.
- Some studies suggest a possible association between calcium supplements and adverse cardiovascular events.
- Existing research has limitations, including compliance issues and potential bias, questioning reported associations.
Purpose of the Study:
- To critically evaluate the evidence linking calcium supplement intake to cardiovascular event risk.
- To assess the strength, consistency, dose-response, and biological plausibility of the hypothesized relationship.
- To determine if current evidence warrants a change in recommendations for calcium supplementation.
Main Methods:
- Review of epidemiological studies and meta-analyses of randomized controlled trials.
- Examination of subgroup analyses, including data from the Women's Health Initiative.
- Application of Bradford Hill criteria for causal inference to assess the calcium-cardiovascular link.
Main Results:
- Methodological limitations in studies reporting adverse cardiovascular events (e.g., bias, confounding) were identified.
- Other cohort studies indicate no detrimental cardiovascular effects from dietary or supplemental calcium, with or without vitamin D.
- Limited evidence supports plausible biological mechanisms connecting calcium supplements to adverse cardiovascular outcomes.
Conclusions:
- The current evidence is insufficient to establish a causal relationship between calcium supplement use and increased cardiovascular disease risk.
- Existing recommendations from the Institute of Medicine for calcium supplementation for bone health should be maintained.
- Further research may be needed, but current data do not support altering supplementation guidelines based on cardiovascular concerns.
Abstract:
A group of academic and industry experts in the fields of nutrition, cardiology, epidemiology, food science, bone health, and integrative medicine examined the data on the relationship between calcium supplement use and risk of cardiovascular events, with an emphasis on 4 of the Bradford Hill criteria for causal inference: strength, consistency, dose-response, and biological plausibility. Results from 2 epidemiological studies and a meta-analysis of randomized, controlled clinical trials, including a subgroup analysis from the Women's Health Initiative, have prompted concern about a potential association between calcium supplement use and a small increase in the risk of adverse cardiovascular events. However, a number of issues with the studies, such as inadequate compliance with the intervention, use of nontrial calcium supplements, potential bias in event ascertainment, and lack of information on and adjustment for known cardiovascular risk determinants, suggest that bias and confounding cannot be excluded as explanations for the reported associations. Findings from other cohort studies also suggest no detrimental effect of calcium from diet or supplements, with or without vitamin D, on cardiovascular disease risk. In addition, little evidence exists for plausible biological mechanisms to link calcium supplement use with adverse cardiovascular outcomes. The authors do not believe that the evidence presented to date regarding the hypothesized relationship between calcium supplement use and increased cardiovascular disease risk is sufficient to warrant a change in the Institute of Medicine recommendations, which advocate use of supplements to promote optimal bone health in individuals who do not obtain recommended intakes of calcium through dietary sources.
Related Concept Videos
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Coronary Artery Disease IV: Preventive Measures
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...